KeraVet Bio, has completed their seed round investment. This exciting milestone propels KeraVet’s flagship product, KeraVet Gel, into their fall launch. The conclusion of this round coincides with the completion of their animal-specific clinical trials work, carried out to further demonstrate the efficacy of the product.
KeraVet Gel has been reformulated from an FDA cleared human medical product utilizing the same keratin based, patent-protected technology to bring first-in-its-class woundcare for dogs and cats. KeraVet Bio aims to redefine the standard of care in wound management by providing dogs and cats a product that supports better wound management that also eliminates the need for an Elizabethan collar (also known as a cone or E-collar) or other physical restraint.
“This investment round is populated by sophisticated investors throughout the animal health industry. It not only solidifies our drive towards launch this year but affirms KeraVet’s commitment to materially improving wound care in pets. We know we have something special and this round is validation from the industry that we are right,” said Dr. Luke Burnett, CEO of KeraVet Bio.
KeraVet Bio has leveraged a robust IP portfolio and a proprietary platform to create keratin-based wound management products for dogs and cats. Tested by over one hundred veterinarians across the country, KeraVet Gel combines and delivers all the most important, necessary components when addressings wounds.
The company has brought on an impressive advisory board of well-known, industry experts and has begun their Series A fundraising round. They have retained Crain & Company to support their strategic growth.